BIOMAT Database Logo BIOMAT Database Logo

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. 2002

Jeannette M Whitcomb, and Wei Huang, and Kay Limoli, and Ellen Paxinos, and Terri Wrin, and Gail Skowron, and Steven G Deeks, and Michael Bates, and Nicholas S Hellmann, and Christos J Petropoulos
ViroLogic Inc, South San Francisco, California 94080, USA.

OBJECTIVE The routine use of phenotypic drug resistance testing in patient management has revealed that many HIV-1 strains possess significantly increased drug sensitivity, or 'hypersusceptibility' compared with wild-type viruses. This study describes hypersusceptibility to non-nucleoside reverse transcriptase inhibitors (NNRTI) and was designed to determine the prevalence of and viral characteristics associated with NNRTI hypersusceptibility in patient-derived viruses. METHODS Retrospective analyses were performed on a large clinical laboratory dataset containing phenotypic drug susceptibility and genotypic sequence results from HIV-1 patient isolates. Genetically engineered viruses were used to confirm the role of certain nucleoside reverse transcriptase inhibitor (NRTI)-resistance mutations in NNRTI hypersusceptibility. RESULTS Hypersusceptibility to delavirdine, efavirenz and nevirapine was detected in 10.7, 10.8 and 8.0% of more than 17,000 consecutive plasma samples submitted for phenotypic susceptibility testing. In analyses limited to a subset of viruses derived from patients with known treatment histories, NNRTI hypersusceptibility was observed significantly more frequently among viruses from NRTI experienced/NNRTI-naive patients compared with viruses from NRTI/NNRTI-naive patients. Significant inverse correlations between NRTI and NNRTI susceptibility exist among the viruses from NRTI-experienced patients. Analyses of viruses classified according to their NNRTI susceptibility identified 18 positions in reverse transcriptase where substitutions were significantly associated with NNRTI hypersusceptibility. CONCLUSIONS NNRTI hypersusceptibility is common among patient HIV-1 isolates, especially in NRTI-resistant viruses. Genotypic correlates of hypersusceptibility are complex and not easily defined by a simple analysis of NRTI-associated resistance mutations. NNRTI hypersusceptibility may provide an explanation for the superior virologic response to NNRTI-containing salvage regimens observed in NRTI-experienced patients in several clinical trials.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences

Related Publications

Jeannette M Whitcomb, and Wei Huang, and Kay Limoli, and Ellen Paxinos, and Terri Wrin, and Gail Skowron, and Steven G Deeks, and Michael Bates, and Nicholas S Hellmann, and Christos J Petropoulos
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
June 2003, AIDS (London, England),
Jeannette M Whitcomb, and Wei Huang, and Kay Limoli, and Ellen Paxinos, and Terri Wrin, and Gail Skowron, and Steven G Deeks, and Michael Bates, and Nicholas S Hellmann, and Christos J Petropoulos
Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
October 2001, HIV medicine,
Jeannette M Whitcomb, and Wei Huang, and Kay Limoli, and Ellen Paxinos, and Terri Wrin, and Gail Skowron, and Steven G Deeks, and Michael Bates, and Nicholas S Hellmann, and Christos J Petropoulos
Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
April 2006, AIDS (London, England),
Jeannette M Whitcomb, and Wei Huang, and Kay Limoli, and Ellen Paxinos, and Terri Wrin, and Gail Skowron, and Steven G Deeks, and Michael Bates, and Nicholas S Hellmann, and Christos J Petropoulos
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations.
August 2004, Journal of acquired immune deficiency syndromes (1999),
Jeannette M Whitcomb, and Wei Huang, and Kay Limoli, and Ellen Paxinos, and Terri Wrin, and Gail Skowron, and Steven G Deeks, and Michael Bates, and Nicholas S Hellmann, and Christos J Petropoulos
Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
January 2006, Journal of medical virology,
Jeannette M Whitcomb, and Wei Huang, and Kay Limoli, and Ellen Paxinos, and Terri Wrin, and Gail Skowron, and Steven G Deeks, and Michael Bates, and Nicholas S Hellmann, and Christos J Petropoulos
Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase.
February 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,
Jeannette M Whitcomb, and Wei Huang, and Kay Limoli, and Ellen Paxinos, and Terri Wrin, and Gail Skowron, and Steven G Deeks, and Michael Bates, and Nicholas S Hellmann, and Christos J Petropoulos
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2006, Current opinion in investigational drugs (London, England : 2000),
Jeannette M Whitcomb, and Wei Huang, and Kay Limoli, and Ellen Paxinos, and Terri Wrin, and Gail Skowron, and Steven G Deeks, and Michael Bates, and Nicholas S Hellmann, and Christos J Petropoulos
Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.
December 2013, Future medicinal chemistry,
Jeannette M Whitcomb, and Wei Huang, and Kay Limoli, and Ellen Paxinos, and Terri Wrin, and Gail Skowron, and Steven G Deeks, and Michael Bates, and Nicholas S Hellmann, and Christos J Petropoulos
[HIV resistance to non-nucleoside reverse transcriptase inhibitors].
August 2006, Virologie (Montrouge, France),
Jeannette M Whitcomb, and Wei Huang, and Kay Limoli, and Ellen Paxinos, and Terri Wrin, and Gail Skowron, and Steven G Deeks, and Michael Bates, and Nicholas S Hellmann, and Christos J Petropoulos
[Mechanisms of HIV-1 drug resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors].
January 2011, Molekuliarnaia biologiia,
Copied contents to your clipboard!